Personalised adaptive basal-bolus algorithm using SMBG/CGM data

Qingnan Sun¹, Marko V. Jankovic^{1,2}, Christoph Stettler³, Stavroula Mougiakakou^{1,3}

¹ARTORG Center for Biomedical Engineering Research, University of Bern, Bern, Switzerland ²Department of the Emergency Medicine, Bern University Hospital "Inselspital", Switzerland ³Division of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital "Inselspital", Switzerland

AvTreat

A Mobile Platform for Personalization of Insulin Delivery based on a Patch Pump and Reinforcement Learning

Background and Aims

An essential component of the diabetes management plan is the glucose monitoring using either meters for selfmonitoring of blood glucose (SMBG) or more recently continuous glucose monitors (CGM).

The main objective of the study is the simultaneous personalisation of the basal and bolus insulin to be delivered by a pump independent of the used glucose monitoring device (SMBG or CGM) using a newly proposed adaptive

Method

ABBA is based on reinforcement learning (RL), a branch of artificial intelligence algorithms, that

"....allows the system to learn its behaviour based on feedback from the environment"

After an initialization phase of seven days using patient's CGM and insulin pump data the ABBA estimates the basal and bolus independently if he/she is using CGM or SMBG.

In silico evaluation and daily scenario

The training version of the FDA accepted UVa/Padova T1DM Simulator v3.2

The scenario lasted for 98 days (Days 2-8 for initialization; Days 9-98 for control).

ABBA

- Glucose concentrations (from SMBG or CGM) Input: of day *i* **Output:** Basal rate for day *i*+1, and three Carbohydrate to Insulin Ratios (CIRs) for breakfast - CIR_B, lunch - CIR₁, and dinner - CIR_D
 - for the day *i*+1
- Three meals (breakfast, lunch and dinner) were considered with variabilities in the announcement of mealtime (\pm 15 min) and carbohydrate amount (\pm 10g for main meals and \pm 5g for snack). In addition, an uncertainty in the order of \pm 50% was introduced to simulate the error of patient's carbohydrate content self-estimations.
- Variable insulin sensitivity (dawn phenomenon -50% from 4:00 AM to 8:00 AM and interday variability in the order of $\pm 25\%$).

Both variabilities and uncertainties follow uniform distributions.

Results						Conclusions
	BG (mg/dL)	% in target range	% in Hypo	% in Hyper	Total daily insulin (U)	
	(mean \pm standard deviation)					demonstrated its ability to achieve
Adults						 glucose control in an in silico
ABBA _{CGM}	140.9 ± 18.4	87.5 ± 16.1	1.0 ± 1.1	11.5 ± 15.4	43.2 ± 10.8	population using a complex scenario
ABBA _{SMBG}	143.5 ± 18.9	86.9 ± 16.7	0.6 ± 0.9	12.5 ± 16.0	42.6 ± 9.9	characterized by a high degree of variabilities and uncertainties,
Adolescents						
ABBA _{CGM}	148.1 ± 11.5	75.7 ± 12.2	2.4 ± 2.0	21.9 ± 12.3	31.6 ± 6.7	 comparable performances for both CGM and SMBG, without affecting the
ABBA _{SMBG}	145.8 ± 9.3	77.8 ± 13.6	2.6 ± 2.2	19.6 ± 12.7	31.8 ± 7.1	total daily insulin dose.
Children						
ABBA _{CGM}	149.3 ± 9.0	75.0 ± 9.8	1.8 ± 1.6	23.2 ± 8.8	15.9 ± 3.8	Next step
ABBA _{SMBG}	150.5 ± 10.8	75.2 ± 12.4	1.1 ± 1.3	23.7 ± 11.5	15.9 ± 3.7	ABBA within the framework of a clinical study

sludy

No statistically significant difference was observed between ABBA_{CGM} and ABBA_{SMBG}, α =0.05 Target range: [70 180] mg/dl; Hypo < 70 mg/dl; Hyper > 180 mg/dl

 $\boldsymbol{u}^{\scriptscriptstyle \mathsf{D}}$ **WINSELSPITAL** UNIVERSITÄTSSPITAL BERN UNIVERSITÄT BERN HOPITAL UNIVERSITAIRE DE BERNE

ARTORG CENTER BIOMEDICAL ENGINEERING RESEARCH BERN UNIVERSITY HOSPITAL

KTI/CTI DIE FÖRDERAGENTUR FÜR INNOVATION L'AGENCE POUR LA PROMOTION DE L'INNOVATION L'AGENZIA PER LA PROMOZIONE DELL'INNOVAZIONE THE INNOVATION PROMOTION AGENCY